V8 Peptides — Engineered Performance
Research Library
Buying PT-141 for Research: What to Evaluate
PT-141Buying Guide

Buying PT-141 for Research: What to Evaluate

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What should a lab evaluate before buying PT-141? Identity first: PT-141 and melanotan II differ only by a C-terminal acid versus amide (about one dalton), so a purity percentage cannot tell them apart. Then check the HPLC method and date, counterion and water content, lot-specific documentation where published, and storage guidance (2–8 °C; −20 °C long term). Supplied for laboratory research use only.

A buyer's guide for a research peptide is useful only if it tells the reader what evidence to ask for and what each piece of evidence can and cannot prove. This one is specific to PT-141 (bremelanotide), a cyclic melanocortin heptapeptide that has a close structural relative, melanotan II, differing by a single terminal group. That near-identity is the single most important quality fact about the molecule and shapes most of the checklist below. Everything stated about V8 material comes from the PT-141 product page; where a document is not published, the guide says so and does not guess.

The article is written for procurement staff and bench scientists who need a defensible record of what they received. It does not rank suppliers, compare any commercial source, or quote any price. It is general guidance about evaluating documentation, and it applies to any laboratory-grade peptide with a few PT-141-specific points.

What the product page actually states

The product page for PT-141 gives these facts: a 10 mg vial; purity of at least 98% by HPLC; the molecular formula C50H68N14O10; the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; a lyophilized powder in a sealed clear glass research vial; storage at 2–8 °C, with −20 °C for the long term and protection from heat, moisture and light; and a research-use-only statement. The page also marks the certificate of analysis as in progress at the time of writing, so a lot-specific certificate should not be assumed. It lists the items that batch documentation covers: compound identity and sequence, measured purity as an HPLC percentage, sequence or identity confirmation, batch or lot number, analytical test date, and supplied form and storage. Those are the items a buyer should expect to be able to check against a certificate where one is published. The table separates what each item establishes from what it leaves open.

Document itemWhat it establishesWhat it does not establish
Sequence and formulaThe intended structure, including the C-terminal groupThat the vial contains that structure; only an analytical identity test shows that
HPLC purity (≥98%)The share of chromatographic peak area belonging to the main peak, at one wavelength and methodPeptide content by mass, water, counterion, or impurities that co-elute or do not absorb
Lot or batch numberTraceability of the vial to a production runAny quality property by itself
Analytical test dateWhen the analysis was runStability after that date
Supplied form and storageThe physical form and the recommended conditionsThat transit conditions were respected
Research-use-only labelThe intended channelAnything about purity or identity

Why PT-141 needs a specific identity check

PT-141 and melanotan II share the same cyclic scaffold and the same residues; the only difference is a free carboxylic acid versus a primary amide at the C-terminus. By the molecular formulas on the two product pages, C50H68N14O10 for PT-141 and C50H69N15O9 for melanotan II, the calculated average masses differ by only about one dalton, roughly 1,025.2 versus 1,024.2 g/mol. A purity figure from reversed-phase HPLC says nothing about which of the two is in the vial, because a single-peak chromatogram is a statement about homogeneity and not identity, and the two compounds are likely to elute close together.

For a laboratory that runs receptor assays, the confusion is not trivial, since a mislabelled analog would shift the interpretation of a selectivity study. The sensible request is therefore a statement of how identity was confirmed, not only that it was. A mass-spectrometric determination with enough resolution to separate a one-dalton difference, or a spiking experiment against an authentic reference, answers the question; a retention-time match to nothing in particular does not. The principles are explained in HPLC vs mass spectrometry and understanding HPLC purity. V8 does not claim any particular method on the product page beyond the listed documentation items, and a buyer who needs a specific method should ask for it in writing before ordering.

Purity: what a percentage hides

Peptides made by solid-phase synthesis carry a recognizable family of by-products: deletion sequences, truncated chains, products of incomplete deprotection, racemized residues and oxidized or modified side chains. A review of related impurities in peptide medicines describes how these arise during solid-phase assembly and why control of them matters (D'Hondt et al., 2014). Cyclization adds its own possibilities, such as incomplete ring closure or dimer formation. A headline figure of "98%" is the area of the main peak as a fraction of the total area at the chosen detection wavelength, which is a useful but incomplete summary.

Four details turn the number into something a lab can use. First, the method: column, gradient, wavelength and integration rules, because a different gradient can split or merge peaks. Second, the date: a number measured at release says little about a vial opened months later. Third, the basis: area percent is not the same as peptide content by weight, which also depends on water and counterion. Fourth, the chromatogram itself, where available, which lets a reader see shoulders and small peaks that the percentage hides. The generic discussion of reading these documents is in how to read a COA and third-party testing explained.

Counterions, water and the gap between mass and molarity

Lyophilized peptides are salts. Because reversed-phase purification commonly uses trifluoroacetic acid, the product is often a trifluoroacetate salt, and the counterion plus residual water can account for a meaningful fraction of the powder mass. This matters for biology: a study in cell culture found that trifluoroacetate at 10 to 100 nM reduced cell numbers and thymidine incorporation in fetal rat osteoblast cultures and that effects were also seen in chondrocytes (Cornish et al., 1999). Whether a particular residual level affects a particular assay is an empirical matter, but the point is general: the counterion is part of the reagent, and sensitive cell assays should record it or control for it.

For arithmetic, the labelled vial mass is the mass of the powder, not necessarily the mass of peptide. A lab that needs exact molar concentration should regard the nominal figure as an upper bound, calculate stock concentration with the formula C = m ÷ (M × V), and confirm it by amino-acid analysis or quantitative UV where precision matters. The reconstitution calculator performs the nominal calculation, and peptide reconstitution volume calculations explains each term.

How the material is made, and why that sets the quality questions

Fmoc solid-phase synthesis is the dominant method for making peptides of this size, and the building blocks are widely available at high quality because of the scale of commercial peptide manufacture (Behrendt et al., 2016). The reason to know this is practical: it tells a buyer which impurities to expect and, therefore, which analytical evidence is relevant. Chain assembly produces deletion and truncation products; cleavage and deprotection produce side-chain adducts; cyclization produces ring-closure variants; and purification and drying produce salt and water content. A manufacturer who has controlled these steps can usually state the method, show the chromatogram and name the identity test. A seller who cannot answer the question has not shown anything about control. Large-scale manufacture of a peptide by chemical synthesis has been described for a 36-residue case (Bray, 2003), and the same logic applies, at a smaller scale, to a seven-residue ring.

A receiving-inspection routine

Documentation is half the record; the other half is what happens when the box arrives. A short routine makes the later data defensible.

  • Compare the label with the order. Compound name, vial size and lot number should match the paperwork.
  • Inspect the vial. A sealed clear glass vial with an intact stopper and crimp; a lyophilized white to off-white cake or loose powder. See peptide vial appearance: what is normal.
  • Log arrival condition. Note date, outer packaging state and temperature of the vial on receipt; return to 2–8 °C or −20 °C storage promptly, as the product page states.
  • Record the lot against the certificate. If a certificate is published for that lot on the COA page, file a copy; if not, note that status in the record instead of assuming.
  • Decide on independent verification. For a study where identity or concentration is critical, plan an in-house or third-party check of a retained sample.
  • Keep a retain. Reserve a small unopened portion or a frozen aliquot for later re-testing.

Questions to put to any supplier before ordering

The questions below are neutral and apply to any source. A clear, specific answer to each is worth more than any marketing claim.

QuestionA useful answer looks likeA weak answer looks like
How was identity confirmed?Names the technique and shows the data for this lot"Verified" with no method
How was purity measured?States the method, wavelength and date; provides the chromatogramA single percentage with no context
Is documentation lot-specific?Certificate carries the lot number and test dateGeneric certificate reused across lots
What is the storage recommendation?Explicit temperature, light and moisture guidanceNo stated conditions
What is the intended use?Clearly labelled for laboratory research use onlySuggests personal or clinical use
What happens if a result disagrees?A described process for investigating a discrepancyNo stated process

General patterns of unreliable sourcing are collected in red flags when buying research peptides, and the wider evaluation framework is in vetting a research peptide supplier. Quality problems in medicines generally have been attributed to poor manufacturing and quality-control practices as well as to deliberate falsification (Johnston and Holt, 2014), which is why process questions matter as much as product questions.

What this guide deliberately leaves out

This article does not say that any lot is certified by an outside body, does not claim that every lot carries a certificate, and does not compare sources. The product page lists the documentation items and marks certificate availability on a per-product basis; where a certificate is marked as in progress, the right course is to regard identity and purity as unverified until it is published or until the lab has tested the material. Mechanism and structure-activity questions are covered elsewhere: see the PT-141 research overview and PT-141 vs melanotan II. The compound is sold for laboratory research use only; the full list is on the shop page.

Frequently asked questions

What should I check first when buying PT-141 for research?

Identity. PT-141 differs from melanotan II only by a free acid versus an amide at the C-terminus, so a purity percentage alone cannot show which one is in the vial. Ask how identity was confirmed for the lot.

How big is the mass difference between PT-141 and melanotan II?

From the formulas on the product pages, the calculated average masses differ by about one dalton: roughly 1,025.2 versus 1,024.2 g/mol. Resolving that needs a suitable mass-spectrometric or spiking test.

Does a 98% HPLC purity mean 98% peptide by weight?

No. It is the main peak area as a share of total peak area at one wavelength. Water, counterion and non-absorbing species are not captured, so peptide content by mass is lower than nominal.

Why does the counterion matter for cell work?

Trifluoroacetate salts are common after reversed-phase purification, and one study found that trifluoroacetate reduced proliferation in osteoblast and chondrocyte cultures (Cornish et al., 1999). Sensitive assays should control for it.

What storage conditions does the PT-141 product page give?

Refrigerate at 2–8 °C, use −20 °C for long-term storage, and protect the vial from heat, moisture and light.

Is a certificate available for every PT-141 lot?

Not currently. The PT-141 product page marks the certificate as in progress, so identity and purity of a lot are unverified until a lot certificate is published on the COA page. Record the status as unverified, or test independently.

What vial size and form is PT-141 supplied in?

A 10 mg size, as a lyophilized powder in a sealed clear glass research vial, according to the product page.

How should I calculate stock concentration?

Use C = m ÷ (M × V): vial mass divided by molar mass and by diluent volume. Regard the nominal mass as an upper bound for peptide content and use the site calculator for the arithmetic.

Should I test material independently?

For studies where identity or exact concentration drives the result, yes. Keep a retained sample and arrange identity and purity testing in house or through an independent laboratory.

Is PT-141 intended for anything other than laboratory research?

No. It is supplied for laboratory research use only and is not a drug, food or cosmetic; it is not intended for human or animal consumption.

Related reading: PT-141 Structure-Activity: Nle, D-Phe and the Ring, PT-141 vs MT-2: Formula, Mass and Analytical Differences, PT-141 vs MT-2: Choosing a Melanocortin Reference Ligand.

References

  1. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
  2. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836
  3. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587-593. doi:10.1038/nrd1133
  4. Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.e779
  5. Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218-243. doi:10.1111/bcp.12298
  6. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.